Are you a journalist?

Learn to know ALK

If you have any queries please feel free to contact Media Relations at ALK headquarters or one of our global offices.

The press releases in this press room contains information that is of general news value for the press, and available for journalists or media with a view to journalistic assessment and preparation before publication.

News

  • Post date
    04/23/2025
    ITULAZAX® tree pollen tablet approved for treatment of children in Europe
  • Post date
    04/03/2025
    Grant of share-based long-term incentive instruments to members of the Board of Management and key employees
  • Post date
    03/13/2025
    Annual General Meeting in ALK-Abelló A/S held on 13 March 2025
  • Post date
    03/07/2025
    ACARIZAX® approved in Canada for treatment of young children
  • Post date
    03/04/2025
    Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff
  • Post date
    02/27/2025
    FDA approves ODACTRA® for the treatment of house dust mite allergy in young children
  • Post date
    02/21/2025
    Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff
  • Post date
    02/19/2025
    Annual General Meeting in ALK-Abelló A/S on 13 March 2025
  • Post date
    02/19/2025
    Annual report 2024: ALK delivers 15% sales growth with profits up 65%

Media Relations

Per Plotnikof
Vice President,
Corporate Communications,
Investor Relations and Strategic Planning
Phone: +45 22612525
Email: PPIDK@alk.net

Jeppe Ilkjær
Media Relations Manager
Corporate Communications
Phone: +45 30502014
Email: Jeppe.Ilkjaer@alk.net

Journalists are always welcome to contact ALK’s Media Relations team.
Steen Riisgaard, CEO
Production facilities, Hørsholm
Image
alk_produktion6_0
Production facilities, Hørsholm
Image
alk_produktion3_1
Production facilities, Hørsholm
Image
alk_produktion5
Production facilities, Hørsholm
Image
Family_website_0
ALK HQ, Hørsholm
Last updated: 2016.11.14